Hormonal aspects of overtraining syndrome: a systematic review FA Cadegiani, CE Kater BMC Sports Science, Medicine and Rehabilitation 9, 1-15, 2017 | 179 | 2017 |
Basal hormones and biochemical markers as predictors of overtraining syndrome in male athletes: the EROS-BASAL study FA Cadegiani, CE Kater Journal of athletic training 54 (8), 906-914, 2019 | 88 | 2019 |
Hypothalamic-pituitary-adrenal (HPA) axis functioning in overtraining syndrome: findings from endocrine and metabolic responses on overtraining syndrome (EROS)—EROS-HPA Axis FA Cadegiani, CE Kater Sports Medicine-Open 3, 1-11, 2017 | 87 | 2017 |
Body composition, metabolism, sleep, psychological and eating patterns of overtraining syndrome: results of the EROS study (EROS-PROFILE) FA Cadegiani, CE Kater Journal of sports sciences 36 (16), 1902-1910, 2018 | 84 | 2018 |
Early antiandrogen therapy with dutasteride reduces viral shedding, inflammatory responses, and Time-to-Remission in males with COVID-19: a randomized, double-blind, placebo … FA Cadegiani, J McCoy, CG Wambier, A Goren Cureus 13 (2), 2021 | 81 | 2021 |
Novel insights of overtraining syndrome discovered from the EROS study FA Cadegiani, CE Kater BMJ Open Sport & Exercise Medicine 5 (1), e000542, 2019 | 79 | 2019 |
Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: results from a randomized, double … FA Cadegiani, J McCoy, CG Wambier, S Vaño-Galván, J Shapiro, A Tosti, ... Cureus 13 (2), 2021 | 76 | 2021 |
Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men A Goren, CG Wambier, S Herrera, J McCoy, S Vaño‐Galván, F Gioia, ... Journal of the European Academy of Dermatology and Venereology 35 (1), e13-e15, 2021 | 70 | 2021 |
Novel causes and consequences of overtraining syndrome: the EROS-DISRUPTORS study FA Cadegiani, CE Kater BMC Sports Science, Medicine and Rehabilitation 11, 1-13, 2019 | 64 | 2019 |
5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia FA Cadegiani, S Herrera | 63 | 2021 |
Proxalutamide reduces the rate of hospitalization for COVID-19 male outpatients: a randomized double-blinded placebo-controlled trial J McCoy, A Goren, FA Cadegiani, S Vaño-Galván, M Kovacevic, M Situm, ... Frontiers in medicine 8, 2021 | 61 | 2021 |
Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS) FA Cadegiani, A Goren, CG Wambier Medical hypotheses 143, 110112, 2020 | 61 | 2020 |
Adrenal fatigue does not exist: a systematic review FA Cadegiani, CE Kater BMC endocrine disorders 16, 1-16, 2016 | 58 | 2016 |
Spironolactone: an anti-androgenic and anti-hypertensive drug that may provide protection against the novel coronavirus (SARS-CoV-2) induced acute respiratory distress syndrome … FA Cadegiani, CG Wambier, A Goren Frontiers in Medicine 7, 453, 2020 | 53 | 2020 |
Clinical and biochemical characteristics of high-intensity functional training (HIFT) and overtraining syndrome: findings from the EROS study (The EROS-HIFT) FA Cadegiani, CE Kater, M Gazola Journal of sports sciences 37 (11), 1296-1307, 2019 | 52 | 2019 |
Hormonal response to a non-exercise stress test in athletes with overtraining syndrome: results from the endocrine and metabolic responses on Overtraining syndrome (EROS)—EROS … FA Cadegiani, CE Kater Journal of Science and Medicine in Sport 21 (7), 648-653, 2018 | 52 | 2018 |
Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known … FA Cadegiani, A Goren, CG Wambier, J McCoy New microbes and new infections 43, 100915, 2021 | 50 | 2021 |
Repurposing existing drugs for COVID-19: an endocrinology perspective FA Cadegiani BMC endocrine disorders 20, 1-19, 2020 | 48 | 2020 |
Clinical symptoms of hyperandrogenic women diagnosed with COVID-19 FA Cadegiani, RK Lim, A Goren, J McCoy, M Situm, M Kovacevic, ... Journal of the European Academy of Dermatology and Venereology: JEADV 35 (2 …, 2021 | 44 | 2021 |
Androgen receptor genetic variant predicts COVID‐19 disease severity: a prospective longitudinal study of hospitalized COVID‐19 male patients J McCoy, CG Wambier, S Herrera, S Vaño‐Galván, F Gioia, B Comeche, ... Journal of the European Academy of Dermatology and Venereology 35 (1), e15, 2021 | 41 | 2021 |